Cocca Alexandra T, Privette Alicia, Leon Stuart M, Crookes Bruce A, Hall Gregory, Lena Jonathan, Eriksson Evert A
Division of Trauma and Critical Care, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina.
Department of Emergency Medicine, Medical University of South Carolina, Charleston, South Carolina.
J Emerg Med. 2019 Dec;57(6):812-816. doi: 10.1016/j.jemermed.2019.09.011. Epub 2019 Nov 14.
The reported risk of delayed intracranial hemorrhage (ICH) in a trauma patient on warfarin is estimated to be between 0.6% and 6%. The risk of delayed ICH in trauma patients taking novel oral anticoagulants (NOACs) is not well-defined.
We hypothesized that there was a significant number of delayed presentations of ICH in patients on NOACs.
A retrospective review of our trauma registry was performed on geriatric patients (age older than 64 years) who were initially evaluated at our level I trauma center, had fall from standing height or less, and were anticoagulated (warfarin or NOACs), from April 2017 to March 2018.
Seventy-seven patients met inclusion criteria. The mean age was 80 ± 7.7 years and 46% of patients were male. The admission head computed tomography scan was positive in 20.8% of patients. Positive scans were more common in patients on warfarin vs. NOACs (30% vs. 14%; p = 0.074) and had a significantly higher Injury Severity Score (median [interquartile range]: 9 [3-15] vs. 5 [1-9]; p = 0.030) and Abbreviated Injury Scale-Head score (median [interquartile range]: 1 [0-3] vs. 1 [0-2]; p = 0.035). The agreement between loss of consciousness (LOC) and ICH was 72% (κ = -0.064; p = 0.263). Fifty-one percent of patients had a repeat head CT. New ICH was diagnosed in 9.6% of patients. All of these patients were on NOACs.
A fall from standing or less in anticoagulated geriatric patients is a significant mechanism of injury resulting in ICH. The absence of LOC does not eliminate the possibility of ICH. There is a significant risk of delayed ICH for patients on NOACs and repeat evaluations should be performed. A prospective multicenter evaluation of this finding is warranted.
据报道,服用华法林的创伤患者发生迟发性颅内出血(ICH)的风险估计在0.6%至6%之间。服用新型口服抗凝剂(NOACs)的创伤患者发生迟发性ICH的风险尚不明确。
我们假设服用NOACs的患者中存在大量迟发性ICH病例。
对2017年4月至2018年3月期间在我院一级创伤中心接受初始评估、从站立高度或更低高度跌倒且正在接受抗凝治疗(华法林或NOACs)的老年患者(年龄大于64岁)的创伤登记资料进行回顾性分析。
77例患者符合纳入标准。平均年龄为80±7.7岁,46%的患者为男性。20.8%的患者入院时头部计算机断层扫描(CT)呈阳性。华法林组患者CT扫描阳性的比例高于NOACs组(30%对14%;p = 0.074),且损伤严重程度评分(中位数[四分位间距]:9[3 - 15]对5[1 - 9];p = 0.030)和简明损伤定级标准-头部评分(中位数[四分位间距]:1[0 - 3]对1[0 - 2];p = 0.035)显著更高。意识丧失(LOC)与ICH之间的一致性为72%(κ = -0.064;p = 0.263)。51%的患者进行了重复头部CT检查。9.6%的患者被诊断为新发ICH。所有这些患者均服用NOACs。
抗凝治疗的老年患者从站立或更低高度跌倒,是导致ICH的重要损伤机制。无LOC并不能排除ICH的可能性。服用NOACs的患者发生迟发性ICH的风险很高,应进行重复评估。有必要对这一发现进行前瞻性多中心评估。